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OBJECTIVEdTranscription factor 7-like 2 (TCF7L2) polymorphisms are strongly associated
with type 2 diabetes, but controversially with plasma lipids and cardiovascular disease. Inter-
actions of the Mediterranean diet (MedDiet) on these associations are unknown.We investigated
whether the TCF7L2-rs7903146 (C.T) polymorphism associations with type 2 diabetes, glu-
cose, lipids, and cardiovascular disease incidence were modulated by MedDiet.
RESEARCHDESIGNANDMETHODSdA randomized trial (two MedDiet intervention
groups and a control group) with 7,018 participants in the PREvención con DIetaMEDiterranea
study was undertaken and major cardiovascular events assessed. Data were analyzed at baseline
and after a median follow-up of 4.8 years. Multivariable-adjusted Cox regression was used to
estimate hazard ratios (HRs) for cardiovascular events.
RESULTSdThe TCF7L2-rs7903146 polymorphism was associated with type 2 diabetes (odds
ratio 1.87 [95% CI 1.62–2.17] for TT compared with CC). MedDiet interacted signiﬁcantly with
rs7903146 on fasting glucose at baseline (P interaction = 0.004).When adherence to theMedDiet
was low, TT had higher fasting glucose concentrations (132.3 6 3.5 mg/dL) than CC+CT
(127.3 6 3.2 mg/dL) individuals (P = 0.001). Nevertheless, when adherence was high, this
increase was not observed (P = 0.605). This modulation was also detected for total cholesterol,
LDL cholesterol, and triglycerides (P interaction, 0.05 for all). Likewise, in the randomized trial,
TT subjects had a higher stroke incidence in the control group (adjusted HR 2.91 [95% CI 1.36–
6.19]; P = 0.006 compared with CC), whereas dietary intervention with MedDiet reduced stroke
incidence in TT homozygotes (adjusted HR 0.96 [95%CI 0.49–1.87]; P = 0.892 for TT compared
with CC).
CONCLUSIONSdOur novel results suggest that MedDiet may not only reduce increased
fasting glucose and lipids in TT individuals, but also stroke incidence.
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A lthough transcription factor 7-like 2(TCF7L2) gene is the strongest andmost widely replicated locus associ-
ated with type 2 diabetes (1–5), there are
very few studies that have examined the
association between genetic variation in
this gene and cardiovascular disease (6–
9). Neither do we know how diet modu-
lates the associations between this gene
and type 2 diabetes, plasma glucose con-
centrations, plasma lipids, other cardio-
vascular risk factors, or cardiovascular
events (10). A deeper understanding of
these associations and dietary interactions
is crucial for improving existing, or de-
signing new, interventions in primary
prevention of cardiovascular diseases
in high-risk subjects. The product of
TCF7L2 is a high-mobility box-containing
transcription factor that plays a role in
activatingmany genes (11,12). Themech-
anism through which the TCF7L2 is
associated with type 2 diabetes has yet
to be determined (13), although various
hypotheses have been proposed (14–17).
The rs7903146 polymorphism (C.T) is
one of the most important genetic var-
iants inﬂuencing type 2 diabetes risk
(18). At present, the prevalence of the
7903146T allele, associated with higher
type 2 diabetes risk, is lower than that
of the C allele in Caucasians. However,
Helgason et al. (19) reported that the
rs7903146T allele is probably the ances-
tral allele, suggesting that changes in its
prevalence are due to positive selection,
driven, among other things, by dietary
factors. Thus, a study (20) highlighted
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C a r d i o v a s c u l a r a n d M e t a b o l i c R i s k
O R I G I N A L A R T I C L E
the north–south gradient for the 7903146T
allele found in Europe, the frequency of
this allele being higher in Mediterranean
populations (;0.4) than in Northern
Europeans (;0.2). Although there is evi-
dence that the Mediterranean food pat-
tern may reduce type 2 diabetes risk
(21) and cardiovascular disease incidence
(22), no studies have investigated the in-
ﬂuence of Mediterranean diet (MedDiet)
on TCF7L2 gene effects. Some investiga-
tions (23–25) have analyzed the interac-
tion between dietary factors and TCF7L2
gene variation on incidence of type 2
diabetes, but the results are inconclu-
sive. In addition to type 2 diabetes risk
and fasting glucose concentrations, the
TCF7L2-rs7903146 polymorphism has
also been associated with other diabetes-
related traits such as plasma lipid concen-
trations (26–28), metabolic syndrome
(29,30), and even with increased ath-
erosclerosis and cardiovascular disease
risk (7–9). Although a few studies have
found interactions among dietary poly-
unsaturated fatty acids, saturated fat, or
proteins in determining plasma lipids
or metabolic syndrome components
(29–32), there are no data on the inﬂu-
ence of an overall healthy food pattern,
such as the MedDiet pattern, in modu-
lating the associations between the
TCF7L2-rs7903146 polymorphism and
these traits.
Moreover, no study has examined the
inﬂuence of a dietary intervention with
MedDiet on the effects of the TCF7L2
polymorphisms on incidence of cardio-
vascular events. Thus, our aims were 1) to
investigate the inﬂuence of prerandomiza-
tion adherence to the MedDiet pattern in
modulating the associations between the
TCF7L2-rs7903146 polymorphism and
fasting glucose, type 2 diabetes, plasma
lipids, and incidence of major cardiovas-
cular diseases (stroke and myocardial in-
farction); and 2) to assess the modulation
of the effect of this polymorphism on the
incidence of these cardiovascular events
through long-term postrandomization
intervention (median ;5 years) with
MedDiet in a large nutrition intervention
trial (22).
RESEARCH DESIGN AND
METHODS
Subjects
We included the 7,018 participants
(2,993 men and 4,025 women) entering
the PREvención con DIetaMEDiterranea
(PREDIMED) trial from whom DNA was
isolated, the TCF7L2-rs7903146 poly-
morphism determined, and who had
valid data for the main clinical and life-
style variables analyzed. The PREDIMED
study is a multicenter clinical trial
(ISRCTN35739639) aimed at assessing
the effects of the MedDiet on the primary
prevention of cardiovascular disease
(22,33). The completion date of this
study was December 2010. The 7,018
participants analyzed did not differ in
the main characteristics from those of
the total cohort (7,447). Details of this
study have been fully described elsewhere
(22,34). Brieﬂy, from October 2003, po-
tential high-cardiovascular-risk subjects
were selected by physicians in pri-
mary care centers. Eligible subjects were
community-dwelling people (aged 55–80
years for men, 60–80 years for women)
who fulﬁlled at least one of two criteria:
type 2 diabetes (35) and three or more
cardiovascular risk factors (hypertension,
dyslipidemia, BMI $25 kg/m2, current
smoking, or a family history of premature
cardiovascular disease). Exclusion criteria
included a personal history of cardiovas-
cular disease, any severe chronic illness,
and drug or alcohol addiction (33). Par-
ticipants were randomly assigned to three
interventions: MedDiet with extra virgin
olive oil (EVOO), MedDiet with mixed
nuts, and control group (low-fat diet).
Participants assigned to both MedDiet
groups received intensive training to
follow the MedDiet and allotments of
either EVOO (50 mL/day) or mixed
nuts (30 g/day) at no cost (22,34). Partic-
ipants assigned to the control diet re-
ceived recommendations to reduce the
intake of all types of fat. A detailed de-
scription of the nutritional interventions
has been provided elsewhere (22). Sub-
jects were followed up for a median of 4.8
years (interquartile range 2.8–5.8 years).
The Institutional Review Board of each
participating center approved the study
protocol, and all participants provided
written informed consent.
Demographic, clinical,
anthropometric, and dietary
measurements
The baseline examination included as-
sessment of standard cardiovascular risk
factors, medication use, sociodemo-
graphic factor, and lifestyle variables, as
previously detailed (33,34). Food con-
sumption was determined by a validated
semiquantitative 137-item food fre-
quency questionnaire (36). The glycemic
index (GI) for food and beverage items
was estimated by using average values
from the 2002 international tables of GI
and glycemic load (GL) and expanded in
2008 (37) with glucose as the reference
food. Dietary GL was calculated consider-
ing the quality and the amount of carbo-
hydrate (GL = [GI 3 amount of available
carbohydrate]/100) (38). A validated 14-
item questionnaire indicating the degree
of adherence to the traditional MedDiet
was also administered (39). Each ques-
tion was scored 0 or 1 (Supplementary
Table 1). The ﬁnal score ranged from 0–
14. The greater the score, the greater the
adherence to the MedDiet. Dichotomous
variables of prerandomization adherence
to the MedDiet and nutrient intake were
created using sample means as cutoff
points. Physical activity was estimated
by the Minnesota Leisure Time Physical
Activity Questionnaire as previously
reported (34). Weight and height were
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TCF7L2, Mediterranean diet, and stroke
measured with calibrated scales and a
wall-mounted stadiometer, respectively.
BMI was calculated as weight in kilograms
divided by the square of height in meters.
Outcome ascertainment
The primary end point was the occurrence
of the major cardiovascular events and
comprised stroke, myocardial infarction,
or cardiovascular death (22). We used four
sources of information to identify end
points: 1) repeated contacts with partici-
pants, 2) family physicians, 3) yearly review
of medical records, and 4) consultation of
the National Death Index. All medical re-
cords related to end points were examined
by the end point adjudication committee,
whose members were blind to treatment
allocation. Only end points conﬁrmed by
the adjudication committee that occurred
between 1 October 2003 and 1 December
2010 were included in the analyses. The
criteria for adjudicating primary outcomes
are detailed elsewhere (22).
Biochemical determinations, DNA
extraction, and genotyping
At baseline, blood samples were obtained
from each participant after an overnight
fast, frozen at2808C, and shipped to cen-
tral laboratories for analyses. Fasting glu-
cose, total cholesterol, triglycerides, HDL
cholesterol (HDL-C), and LDL cholesterol
(LDL-C) were measured using standard
enzymatic automated methods as previ-
ously described (33). In patients whose
triglyceride levels were ,400 mg/dL,
LDL-C concentrations were estimated us-
ing the Friedewald formula. Biochemical
data could not be obtained for all of the
7,018 participants at baseline (ranging
from n = 6,568 for total cholesterol and
6,201 for fasting glucose).
Genomic DNA was extracted from
buffy coat with the MagNaPure LC
DNA solation Kit (Roche Diagnostics,
Mannheim, Germany). The TCF7L2-
rs7903146 was genotyped on a 7900HT
Sequence Detection System (Applied Bio-
systems, Foster City, CA) using a ﬂuores-
cent allelic discrimination TaqMan assay.
The calling rate was .95%; 5% of sam-
ples were randomly selected and geno-
typed a second time, and there were no
discrepancies.
Statistical analyses
The x2 tests were used to test differ-
ences in percentages. Triglycerides were
log-transformed for statistical analyses.
The t and ANOVA tests were applied
to compare crude means. Multivariate
adjustments for continuous variables
were carried out by covariance analysis.
Models were adjusted for age, sex, BMI,
type 2 diabetes, total energy intake, alco-
hol consumption, smoking, physical ac-
tivity, and medications (antidiabetic,
lipid-lowering, and antihypertensive
drugs). Dichotomous variables for dietary
intake and physical activity were created
using as cutoff the sample means. Logistic
regression methods were also used for
prevalence of type 2 diabetes. To test
the interaction between the TCF7L2-
rs7903146 polymorphism, adherence to
MedDiet, or the other dietary variables
on cardiovascular risk factors at baseline,
separate multivariate regression models
including the corresponding main effects
and interaction terms in addition to con-
trol for potential confounders were ﬁtted
assuming codominant or recessive genetic
effects. Stratiﬁed analyses were also car-
ried out. To examine the association be-
tweenMedDiet and cardiovascular events,
we used Cox regression models with the
length of follow-up as the primary time
variable. The exposure time was calcu-
lated as the time between recruitment
and the date of death for deceased partic-
ipants or the last study visit or the last re-
corded clinical event of participants who
did not die. We evaluated the association
between both prerandomization adher-
ence to the MedDiet (low and high) and
the postrandomization intervention with
MedDiet (analyses were based on the
intention-to-treat principle) and cardio-
vascular events. Hazard ratios (HRs) with
95% CI for the TCF7L2-rs7903146 geno-
types were calculated and stratiﬁed by
MedDiet (prerandomization adherence
to the MedDiet or intervention with
MedDiet, pooling together the groups sup-
plemented with EVOO and nuts vs. the
control group). In the multivariable model
1, covariates were sex, age, and recruitment
center and intervention group. Amultivari-
able model 2 was also ﬁtted including ad-
ditional adjustment for type 2 diabetes,
BMI, smoking, drinking, total energy in-
take, and prerandomization adherence to
theMedDiet. Kaplan-Meier survival curves
were plotted to estimate the probability of
remaining free of myocardial infarction
during follow-up. Statistical analyses were
performed with the SPSS package, version
17.0 (SPSS, Chicago, IL). All tests were
two-tailed, and P values ,0.05 were con-
sidered statistically signiﬁcant.
RESULTSdTable 1 shows demo-
graphic, biochemical, clinical lifestyle,
and genetic characteristics of the 7,018
participants in the PREDIMED study at
baseline according to the randomized
allocation to the three dietary intervention
groups: MedDiet supplemented with
EVOO, MedDiet supplemented with
nuts, and control group. In the whole
population, prevalence of type 2 diabetes,
dyslipidemia, obesity, and hypertension
was high. We did not ﬁnd signiﬁcant dif-
ferences in medication use among the in-
tervention groups at baseline: 48.0% of
subjects were on lipid-lowering drugs,
72.5% on antihypertensive drugs, 32.1%
on oral hypoglycemic agents, and 6.9%
on insulin. In the whole population,
mean prerandomization adherence to
MedDiet was 9 6 2 points. For the
TCF7L2-rs7903146, overall prevalence
of TT individuals was 14.2%. Genotype
frequencies did not deviate from Hardy-
Weinberg equilibrium expectations
(P = 0.380).
Association between the TCF7L2-
rs7903146 polymorphism and type 2
diabetes, fasting glucose, and plasma
lipid concentrations at baseline
As expected, this polymorphism pre-
sented a highly signiﬁcant association
with type 2 diabetes (Supplementary
Table 2), TT individuals having greater
risk compared with CC homozygotes
(odds ratio 1.87 [95% CI 1.62–2.17]).
We also observed a highly signiﬁcant
association (P , 0.001) between the
polymorphism and fasting glucose.
This association remained statistically
signiﬁcant even after adjustment for
type 2 diabetes, although losing much
of its statistical signiﬁcance (P = 0.021).
We did not observe any signiﬁcant
associations between the TCF7L2-
rs7903146 polymorphism and plasma
lipids (total cholesterol, triglycerides,
LDL-C, and HDL-C at baseline in the
population as a whole) (Supplementary
Table 2).
Gene–diet interactions of the
TCF7L2-rs7903146 polymorphism
and prerandomization adherence
to the MedDiet on type 2 diabetes
and fasting glucose
We did not ﬁnd a statistically signiﬁcant
interaction between adherence to the
MedDiet (low and high strata based on
the population mean) and the TCF7L2-
rs7903146 polymorphism in determining
prevalence of type 2 diabetes (P interac-
tion: 0.251). Likewise, no statistically
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signiﬁcant interactions were detected
when two categories of other dietary
variables (carbohydrates, ﬁber, GI, GL, to-
tal fat, saturated fat, and proteins) were
analyzed (results not shown). This may
be due in part to the fact that we are deal-
ing with prevalent cases of type 2 diabe-
tes. Therefore, we analyzed how current
fasting glucose concentrations are modu-
lated by the MedDiet and the TCF7L2
polymorphism to better understand the
relationship between present dietary
intake and a TCF7L2 polymorphism-
related trait.
We detected a statistically signiﬁcant
interaction (P = 0.014) between the
TCF7L2 polymorphism (three categories)
and prerandomization adherence to the
MedDiet as dichotomous in determining
fasting glucose concentrations (Supple-
mentary Fig. 1A). When adherence to
MedDiet was low (below the sample
mean, 9 points), we observed the predict-
able effects of the TCF7L2-rs7903146
polymorphism on fasting glucose con-
centrations (higher concentrations in TT
individuals), reaching statistically signiﬁ-
cant results (P = 0.001) even after adjust-
ment for type 2 diabetes, BMI, and other
confounding variables. However, when
adherence to MedDiet was high ($9
points), no higher fasting glucose
concentrations were observed in TT indi-
viduals (P = 0.282). As the effects of this
interaction were mainly observed for TT
individuals, we analyzed them in compar-
ison with CC+CT in a recessive model,
and a more statistically signiﬁcant inter-
action term was obtained (P = 0.004).
This interaction effect (as recessive) was
also statistically signiﬁcant on consider-
ing the score of adherence to MedDiet
as a continuous variable from 0 to 14
(P interaction: 0.033) (Supplementary
Fig. 1B). In a sensitivity analysis, we also
studied the homogeneity of this interaction
in different strata (Table 2). By sex, the in-
teraction effect was statistically signiﬁcant
in both men and women. When we strat-
iﬁed the analysis according to diabetes
status, the interaction effect was higher
and clearly signiﬁcant for type 2 diabetes
subjects (P interaction: 0.023). In nondi-
abetic subjects, although a similar trend
was observed, the interaction term was
borderline signiﬁcant (P = 0.057). How-
ever, the test of heterogeneity for the in-
teraction among the polymorphism,
MedDiet, and type 2 diabetes was not sta-
tistically signiﬁcant (P = 0.348).
We also analyzed the gene–diet inter-
action of other dietary variables (GL, GI,
total fat, saturated fat, ﬁber, carbohydrates,
and proteins) on fasting glucose at baseline
and for neither of them did we ﬁnd statis-
tically signiﬁcant interactions (not shown).
Interaction between
prerandomization adherence to the
MedDiet and the TCF7L2-rs7903146
polymorphism on plasma lipid
concentrations
Using the same recessive interaction
model, we found statistically signiﬁcant
gene–diet interactions (Supplementary
Table 3) in determining total cholesterol,
LDL-C, and triglycerides (P interaction:
0.005, 0.003, and 0.046, respectively).
When adherence to MedDiet was low, TT
individuals presented higher concentra-
tions of total cholesterol, LDL-C, and triglyc-
erides than CC+CT subjects. However,
when adherence was high, these effects
were not observed in TT individuals, and
plasma concentrations of these parameters
did not differ between genotypes. No signif-
icant interaction was detected for HDL-C.
Table 1dDemographic, clinical, lifestyle, and genetic characteristics of the study participants at baseline according to the
intervention groups
Total
(n = 7,018)
MedDiet with EVOO
(n = 2,411)
MedDiet with nuts
(n = 2,314)
Control group
(n = 2,291)
Age (years) 67.0 6 6.2 67.0 6 6.2 66.6 6 6.1 67.3 6 6.3
BMI (kg/m2) 30.0 6 3.9 29.9 6 3.7 29.7 6 3.8 30.2 6 4.0
Waist circumference (cm) 100.4 6 10.6 100.2 6 10.3 100.3 6 10.5 100.8 6 10.7
Female sex [n (%)] 4,025 (57.4) 1,418 (58.8) 1,242 (53.6) 1,365 (59.6)
Current smokers [n (%)] 989 (14.1) 338 (14.0) 334 (14.4) 317 (14.8)
Type 2 diabetes [n (%)] 3,411 (48.6) 1,207 (50.1) 1,081 (46.7) 1,123 (49.0)
Hypertension [n (%)] 5,801 (82.7) 1,974 (81.9) 1,913 (82.6) 1,914 (83.5)
Dyslipidemia [n (%)] 5,063 (72.1) 1,725 (71.5) 1,692 (73.1) 1,646 (71.8)
TCF7L2-rs7903146 [n (%)]
CC 2,770 (39.5) 953 (39.5) 889 (38.4) 928 (40.5)
CT 3,249 (46.3) 1,124 (46.6) 1,091 (47.1) 1,034 (45.1)
TT 999 (14.2) 334 (13.9) 336 (14.5) 329 (14.4)
Energy intake (kcal/day) 2,276 6 607 2,288 6 611 2,316 6 608 2,221 6 597
Total fat (% energy) 39.2 6 6.8 39.2 6 6.9 39.4 6 6.5 39.0 6 6.9
Saturated fat (% energy) 10.0 6 2.3 10.0 6 2.2 10.0 6 2.2 10.0 6 2.3
MUFA (% energy) 19.5 6 4.6 19.5 6 4.6 19.5 6 4.3 19.3 6 4.9
Proteins (% energy) 16.6 6 2.8 16.6 6 2.9 16.5 6 2.7 16.6 6 2.8
Carbohydrates (% energy) 41.9 6 7.2 41.7 6 7.2 42.0 6 7.0 42.3 6 7.2
GI 130.1 6 51.4 130.5 6 52.3 131.3 6 51.2 128.4 6 50.5
GL (g) 53.6 6 5.9 53.5 6 6.1 53.7 6 5.7 53.7 6 58.6
Adherence to the MedDiet 8.6 6 2.0 8.7 6 2.0 8.7 6 2.0 8.4 6 2.1
Alcohol consumption (g/day) 8.4 6 14.1 8.4 6 14.3 9.2 6 15.0 7.4 6 13.1
Physical activity (kcal/day) 231 6 240 232 6 233 248 6 246 215 6 241
Data are mean 6 SD for continuous variables and n (%) for categorical variables. MUFA, monounsaturated fatty acids.
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Association between the TCF7L2-
rs7903146 polymorphism and
incidence of cardiovascular
events after 4.8 years of follow-up:
modulation by prerandomization
adherence to the MedDiet
After a median follow-up of 4.8 years
(interquartile range 2.8–5.8 years), 262
major cardiovascular events occurred
among the 7,018 participants analyzed
(30,359 person-years of observation). Of
these, 130 were strokes, 98 were myocar-
dial infarctions, and the others were cardio-
vascular deaths. In the whole population,
we did not observe statistically signiﬁ-
cant associations between the TCF7L2-
rs7903146 polymorphism and any car-
diovascular event (P = 0.450 for total
cardiovascular events, P = 0.170 for
stroke, and P = 0.849 for myocardial in-
farction). HRs (95% CI) for TT subjects
compared with CC homozygotes were
1.22 (0.85–1.75) for total cardiovascular
events and 1.55 (0.95–2.53) for stroke in-
cidence in a model adjusted for sex, age,
center, type 2 diabetes, and dietary inter-
vention group. Further adjustment for
other covariates did not change the signiﬁ-
cance of results. In the stratiﬁed analysis by
type 2 diabetes, we observed higher HRs
in subjects with type 2 diabetes, but the
results did not reach statistical signiﬁcance.
On analyzing total cardiovascular
events by levels of prerandomization ad-
herence to the MedDiet, the risk associ-
ated with the TT genotype compared with
CC individuals tended to be higher in the
lower stratum (,9 points) of adherence,
but did not reach statistical signiﬁcance
(Supplementary Table 4). Moreover, on
considering stroke incidence, we ob-
tained statistically signiﬁcant results
(Supplementary Table 4). When preran-
domization adherence to MedDiet was
low, TT subjects presented higher risk of
stroke than CC homozygotes (HR 2.44
[95% CI 1.26–4.72] in the adjusted
model including diabetes). No higher
risk was found when adherence to
MedDiet was high (HR 0.99 [95% CI
0.44–2.22] in the adjusted model includ-
ing diabetes). Nomodiﬁcation of the effect
was detected for myocardial infarction
(not shown).
Effect of the intervention with
MedDiet on the association between
the TCF7L2-rs7903146 polymorphism
and incidence of cardiovascular
events after 4.8-year
postrandomization follow-up
The most important results of the current
study, as they came from a randomized
trial and have a higher level of evidence,
were obtained when considering the in-
tervention with MedDiet (Table 3).
Changes in dietary intake by intervention
groups in the PREDIMED study have
been widely detailed in our previous
work (22). After a mean of 4.8 years of
follow-up, we observed a signiﬁcantly
higher incidence of stroke in TT subjects
in the control group (HR 3.06 [95% CI
1.43–6.59] in the adjusted model includ-
ing diabetes) compared with CC homozy-
gotes, but no signiﬁcantly higher risks
were observed in the MedDiet interven-
tion groups either when grouped together
(HR 1.02 [95% CI 0.52–1.99] for TT
compared with CC) or considered sepa-
rately (HR 1.13 [95% CI 0.49–2.64] in
the MedDiet + EVOO and HR 0.89
[95% CI 0.26–2.99] in the MedDiet +
nuts). Although we did not observe statis-
tically signiﬁcant differences between CT
and CC individuals in determining stroke
risk in the control group (P = 0.063), it
should be noted that the CT group is in-
termediate in terms of the magnitude of
risk. This trend toward a gene-dosage effect
contributes to increasing the causality of
our stroke-related ﬁndings. Figure 1 shows
cumulative stroke free-survival per
TCF7L2-rs7903146 genotypes in the con-
trol group (Fig. 1A) and the MedDiet inter-
vention groups (Fig. 1B).
CONCLUSIONSdIn this study un-
dertaken on a large sample of high-
cardiovascular-risk subjects, we found,
consistent with previous studies (1–5,10),
that the TCF7L2-rs7903146 polymor-
phism is a strong genetic determinant
of type 2 diabetes risk and fasting glu-
cose concentrations, TT individuals being
those who presented a higher preva-
lence of type 2 diabetes and higher fasting
glucose. In this study, however, we have
described for the ﬁrst time that preran-
domization adherence to the MedDiet is
capable of modulating the effects of the
TCF7L2-rs7903146 polymorphism on
fasting glucose concentrations, so that a
higher adherence to the MedDiet attenu-
ates the genetic increase of fasting glucose
concentrations in TT individuals. We
have consistently observed this effect in
the whole population and in both men
and women. Moreover, and more impor-
tant, we have described for the ﬁrst time
that dietary intervention with a randomly
assigned MedDiet may modulate the
association of the TCF7L2-rs7903146
polymorphism with stroke incidence. Al-
though several previous studies have an-
alyzed the association between TCF7L2
Table 2dInteraction between the TCF7L2 polymorphism (recessive model) and
prerandomization adherence to the MedDiet in determining fasting plasma glucose
concentrations
Strata/adherence
to MedDiet
TCF7L2-rs7903146 genotypes P value†
(TCF7L2
genotype)
P value‡
(interaction
genotype 3 diet)CC+CT (n = 5,325) TT (n = 876)
Whole population 0.004
Low (,9) (n = 2,833) 127.3 6 3.2 132.3 6 3.5 0.001
High ($9) (n = 3,368) 127.9 6 3.1 127.2 6 3.5 0.605
Men 0.01
Low (,9) (n = 1,170) 135.6 6 5.7 141.2 6 5.6 0.031
High ($9) (n = 1,491) 135.8 6 5.6 135.5 6 6.0 0.814
Women 0.048
Low (,9) (n = 1,663) 126.1 6 3.9 130.5 6 4.4 0.029
High ($9) (n = 1,877) 127.3 6 3.9 126.0 6 4.3 0.596
Type 2 diabetic subjects 0.023
Low (,9) (n = 1,438) 149.4 6 6.1 156.3 6 6.6 0.008
High ($9) (n = 1,583) 149.4 6 6.0 148.3 6 6.6 0.724
Nondiabetic subjects 0.057
Low (,9) (n = 1,395) 99.2 6 0.5 101.8 6 1.2 0.069
High ($9) (n = 1,785) 100.3 6 0.5 100.1 6 1.2 0.732
Data are multivariate adjusted means (mg/dL) 6 SE unless otherwise indicated. †P value for the TCF7L2
genotype in each strata after multivariate adjustment for sex, age, center, type 2 diabetes, BMI, medications,
total energy intake, alcohol consumption, smoking, and physical activity. ‡P value for the interaction term
between the TCF7L2 polymorphism and adherence to the MedDiet in the multivariate adjusted model for
each stratum analyzed.
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polymorphisms and cardiovascular risk,
the results are controversial (6–9,40). In
the ﬁrst report of the Atherosclerosis Risk
in Communities (ARIC) study (6), TCF7L2
polymorphisms were not signiﬁcantly as-
sociated with incident coronary heart dis-
ease, ischemic stroke, or cardiovascular
disease in the whole cohort, although
greater risk was found in white patients
with diabetes (HR 1.21; P = 0.04). Some
years later, a second reanalysis of the ARIC
study (8) reported a higher risk of coronary
heart disease among lean TT individuals
(HR 1.42 [95%CI 1.03–1.97]). Muendlein
et al. (40), using a population of Austrian
patients undergoing coronary angiography,
did report a higher risk of coronary athero-
sclerosis associated with the 7903146T al-
lele for the whole population (odds ratio
1.29 [95% CI 1.09–1.53]), but, in the
stratiﬁed analysis by diabetes status,
they found that this association was
strong in type 2 diabetes patients but
not in nondiabetic subjects. Conversely,
Sousa et al. (7) found in Brazilian patients
that the 7903146T allele was associated
with a higher prevalence and severity of
coronary atherosclerosis in nondiabetic
patients. These contradictory results
may be due to either the different demo-
graphic and clinical characteristics of the
patients included in each study or to the
contribution of interactions with differ-
ent environmental factors.
In our study, although we did not ﬁnd
any signiﬁcant association of the TCF7L2-
rs7903146 polymorphism with cardiovas-
cular events on the population as a whole,
we did ﬁnd a very important modulation
by the MedDiet on stroke incidence. TT
individuals with a lower prerandomization
adherence to MedDiet presented a statisti-
cally signiﬁcant higher stroke risk than CC
individuals. More important is that, de-
spite this starting point, the intervention
with MedDiet over a median of 4.8 years
follow-up had a greater inﬂuence on
stroke. Hence, TT individuals assigned to
the control group presented a higher stroke
incidence than CC individuals. However,
stroke incidence was not greater in TT in-
dividuals in the MedDiet intervention
groups, so reversing the genetic suscepti-
bility conferred by the TCF7L2-rs7903146
polymorphism. These results are espe-
cially important given that the alloca-
tion to the MedDiet intervention was
randomly assigned. No previous study
has analyzed the dietary modulation of
the TCF7L2-rs7903146 polymorphism
on cardiovascular events, so more studies
are required to conﬁrm our ﬁndings.
We do not know the mechanisms by
which this modulation takes place, but
the results obtained in our study do
show a signiﬁcant gene–diet interaction
between the rs7903146 polymorphism
and prerandomization adherence to the
MedDiet in determining fasting glucose
and plasma lipids, so that higher adher-
ence results in a lower concentration of
these cardiovascular risk factors in TT in-
dividuals compared with that which they
would have with a lower adherence to the
MedDiet. The association of the TCF7L2-
rs7903146 polymorphism with plasma
lipids is controversial, and we found great
variability in results depending on the dif-
ferent populations analyzed (26–30),
suggesting a possible modulation of this
association by diet. Although no previous
Table 3dIncidence rates and HRs for total cardiovascular events and stroke stratiﬁed by the TCF7L2-rs7903146 polymorphism and
the dietary intervention group after a median of 4.8 years of follow-up (multivariate adjusted models)
Dietary intervention group in the follow-up
Control group (n = 2,291) MedDiet groups† (n = 4,727)
Cases
Incidence* rate/1,000
person-years HR 95% CI P value Cases
Incidence* rate/1,000
person-years HR 95% CI P value
Outcome
Total cardiovascular
events‡
TCF7L2 (Model 1)
CC 36 9.7 1.00 (Reference) 61 7.5 1.00 (Reference)
CT 47 11.3 1.17 (0.76–1.81) 0.475 73 7.3 0.95 (0.68–1.34) 0.781
TT 18 14.0 1.55 (0.87–2.74) 0.134 27 9.0 1.16 (0.74–1.84) 0.504
TCF7L2 (Model 2)
CC 1.00 (Reference) 1.00 (Reference)
CT 1.13 (0.73–1.75) 0.581 0.91 (0.64–1.26) 0.531
TT 1.43 (0.80–2.54) 0.229 1.04 (0.66–1.65) 0.848
Strokex
TCF7L2 (Model 1)
CC 14 3.8 1.00 (Reference) 31 3.8 1.00 (Reference)
CT 29 6.9 1.89 (0.98–3.53) 0.057 30 3.0 0.78 (0.49–1.28) 0.328
TT 14 10.9 3.19 (1.51–6.75) 0.002 12 4.0 1.06 (0.54–2.08) 0.856
TCF7L2 (Model 2)
CC 1.00 (Reference) 1.00 (Reference)
CT 1.84 (0.97–3.50) 0.063 0.79 (0.46–1.36) 0.386
TT 2.91 (1.36–6.19) 0.006 0.96 (0.49–1.87) 0.892
Model 1, multivariate model adjusted for sex, age, center, and dietary intervention group; Model 2, variables in model 1 plus type 2 diabetes, BMI, total energy intake,
smoking, drinking, and adherence to MedDiet at baseline. *Crude incidence rates were expressed per 1,000 person-years of follow-up. †MedDiet + EVOO and
MedDiet + nuts groups were pooled. ‡Total cardiovascular events is a composite end point including incident nonfatal myocardial infarction, nonfatal stroke, and
cardiovascular deaths. xTotal stroke incidence.
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study has analyzed the inﬂuence of the
MedDiet on this association, some gene–
diet interactions have indeed been de-
scribed between TCF7L2 polymorphisms
and several macronutrients in determining
plasma lipids; e.g., with dietary polyunsat-
urated fatty acids in determining fasting
VLDL concentrations and postprandial
triglyceride-rich lipoproteins in the Genetics
of Lipid-Lowering Drugs and Diet Net-
work (GOLDN) study (31) and with sat-
urated fat on the metabolic-syndrome
related variables in the LIPGENE study
(29). Our ﬁndings, however, go further
as we have found an interaction with
the whole dietary pattern instead of in-
dividual components.
Considering the gene–diet interac-
tion with MedDiet that we have found
on glycemia and lipids, lower plasma con-
centrations of these atherogenic factors
would lead over time to lower stroke in-
cidence in TT subjects on a MedDiet than
in those who are not. The modulation of
stroke incidence by MedDiet is observed
equally in theMedDiet + EVOOand in the
MedDiet + nuts intervention groups, so
that our results suggest once again that
it is the overall MedDiet pattern rather
than speciﬁc foods that contribute to not
increasing stroke risk in TT individuals.
Although we also have found that TT in-
dividuals randomly assigned to the con-
trol group had a higher incidence of total
cardiovascular events, our results did not
reach the statistical signiﬁcance. Taking
into account that we have reported
(22) a higher effect of the intervention
with MedDiet on reducing stroke inci-
dence than myocardial infarction, the re-
sults obtained in our work for the
TCF7L2-rs7903146 polymorphism are
in line with this observation. The major
strength of our study is the large sample
size in a long-term nutritional interven-
tion randomized trial with MedDiet,
which presents the highest level of evi-
dence in nutritional studies. However,
the interactive ﬁndings on stroke risk af-
ter intervention with MedDiet rest on rel-
atively few stroke cases. Despite this
limitation, the fact that the results ob-
tained, when considering adherence to
the MedDiet at baseline go in the same
direction, strengthens this gene–diet
interaction.
In conclusion, we have described for
the ﬁrst time that the association between
the TT genotype and fasting glucose is
modulated by adherence to the MedDiet.
This interaction occurs not only for fast-
ing glucose but also for lipids. A greater
Figure 1dCumulative stroke free-survival by TCF7L2-rs7903146 genotypes in the control
group (A) (n = 2,291) and in the MedDiet intervention groups (B) (n = 4,827). Cox regression
models with outcome of stroke and the TCF7L2-rs7903146 polymorphism (CC, CT, and TT)
adjusted by sex, age, center, type 2 diabetes, BMI, intervention group, alcohol, smoking, total
energy intake, and adherence to the MedDiet at baseline. The P values for the TCF7L2 poly-
morphism and for the corresponding genotypes (CT vs. CC or TT vs. CC) were obtained in the
multivariable adjusted models.
care.diabetesjournals.org DIABETES CARE, VOLUME 36, NOVEMBER 2013 3809
Corella and Associates
prerandomization adherence to MedDiet
leads to a reduction in fasting glucose,
total cholesterol, LDL-C, and triglycerides
in TT individuals who have high genetic
susceptibility to increased levels com-
pared with other genotypes. Importantly,
we observed that intervention with a ran-
domly assigned MedDiet reduced the risk
of stroke in TT individuals. These results,
based on a dietary intervention study,
support the beneﬁts of a MedDiet, espe-
cially for genetically susceptible individ-
uals, and emphasize the importance of
studying entire dietary patterns rather
than individual components.
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